相关实验视频

Updated: Feb 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

与艾滋病毒相关的晚期肺癌中的PD-1/PD-L1阻塞:从机制到临床实践

Ruifang Chen1, Shuai Ren1, Haicheng Tang1

  • 1Department of Respiratory and Critical Care Medicine, Shanghai Public Health Clinical Center, Shanghai, China.

Frontiers in immunology
|February 26, 2026
PubMed
概括

编程细胞死亡蛋白-1 (PD-1) /PD-L1抑制剂在接受抗逆转录病毒治疗 (ART) 的HIV阳性肺癌患者中显示出有前途. 这些疗法可能会增强抗瘤活性并恢复免疫功能,但需要进一步的试验.

关键词:
艾滋病病毒 艾滋病病毒 艾滋病病毒这是一种PD-1抑制剂.这是一种PD-L1抑制剂.免疫疗法 免疫疗法肺癌是一种肺癌.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

相关概念视频

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54